Amgen expected to mount a `very aggressive' defense if FTC sues to block Horizon Therapeutics - CNBC
JHVEPhoto/iStock Editorial via Getty Images

Amgen (NASDAQ:AMGN) is expected to mount a "very aggressive" defense if the Federal Trade Commission files a lawsuit to block the $28 billion acquisition of Horizon Therapeutics (NASDAQ:HZNP), according to CNBC.
FTC commissioners have not yet met on the Horizon/Amgen deal and haven't voted, according to CNBC's David Faber, who cited sources familiar.

Several media reports from Monday indicated that the FTC is preparing a lawsuit as soon as Tuesday to block the combination. 

Horizon Therapeutics (HZNP) shares plunged as much as 19% amid the news reports, though pared decline to 15.5% on the CNBC update.
An Amgen spokesperson told Seeking Alpha in an email Monday night that the company is not aware of any decision made by the Commission. The biotech firm will provide "any appropriate updates when we have more information."
Developing story ....